<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2020-2-109-113</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1314</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Evaluation of the population safety of nonsteroidal anti-inflammatory drugs in the framework of the Pan-European SOS program: focus on aceclofenac</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка популяционной безопасности нестероидных противовоспалительных препаратов в рамках общеевропейской программы SOS: фокус на ацеклофенак</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">aekarat@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>19</day><month>04</month><year>2020</year></pub-date><volume>12</volume><issue>2</issue><fpage>109</fpage><lpage>113</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Karateev A.E., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Каратеев А.Е.</copyright-holder><copyright-holder xml:lang="en">Karateev A.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1314">https://nnp.ima-press.net/nnp/article/view/1314</self-uri><abstract/><trans-abstract xml:lang="ru"/><kwd-group xml:lang="ru"><kwd>нестероидные противовоспалительные препараты</kwd><kwd>ацеклофенак</kwd><kwd>риск осложнений</kwd><kwd>желудочно-кишечное кровотечение</kwd><kwd>сердечная недостаточность</kwd><kwd>ишемический инсульт</kwd><kwd>инфаркт миокарда</kwd></kwd-group><kwd-group xml:lang="en"><kwd>nonsteroidal anti-inflammatory drugs</kwd><kwd>aceclofenac</kwd><kwd>risk of complications</kwd><kwd>gastrointestinal bleeding</kwd><kwd>heart failure</kwd><kwd>ischemic stroke</kwd><kwd>myocardial infarction</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией ООО «Гедеон Рихтер Фарма».</funding-statement><funding-statement xml:lang="en">This article has been supported by Gedeon Richter.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">De Lima L, Radbruch L. The International Association for Hospice and Palliative Care: Advancing Hospice and Palliative Care Worldwide. J Pain Symptom Manage. 2018 Feb;55(2S):S96-S103. doi: 10.1016/j.jpainsymman.2017.03.023. Epub 2017 Aug 8.</mixed-citation><mixed-citation xml:lang="en">De Lima L, Radbruch L. The International Association for Hospice and Palliative Care: Advancing Hospice and Palliative Care Worldwide. J Pain Symptom Manage. 2018 Feb;55(2S):S96-S103. doi: 10.1016/j.jpainsymman.2017.03.023. Epub 2017 Aug 8.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Brennan F, Carr D, Cousins M. Access to Pain Management-Still Very Much a Human Right. Pain Med. 2016 Oct;17(10):1785-1789.</mixed-citation><mixed-citation xml:lang="en">Brennan F, Carr D, Cousins M. Access to Pain Management-Still Very Much a Human Right. Pain Med. 2016 Oct;17(10):1785-1789.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lohman D, Schleifer R, Amon JJ. Access to pain treatment as a human right. BMC Med. 2010 Jan 20;8:8. doi: 10.1186/1741-7015-8-8.</mixed-citation><mixed-citation xml:lang="en">Lohman D, Schleifer R, Amon JJ. Access to pain treatment as a human right. BMC Med. 2010 Jan 20;8:8. doi: 10.1186/1741-7015-8-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Abbasi AB, Salisbury-Afshar E, Berberet CE, et al. Opioid Prescribing Patterns Before Fatal Opioid Overdose. Am J Prev Med. 2020 Feb; 58(2):250-253. doi: 10.1016/j.amepre.2019.09.022.</mixed-citation><mixed-citation xml:lang="en">Abbasi AB, Salisbury-Afshar E, Berberet CE, et al. Opioid Prescribing Patterns Before Fatal Opioid Overdose. Am J Prev Med. 2020 Feb; 58(2):250-253. doi: 10.1016/j.amepre.2019.09.022.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shipton EA, Shipton EE, Shipton AJ. A Review of the Opioid Epidemic: What Do We Do About It? Pain Ther. 2018 Jun;7(1):23-36. doi: 10.1007/s40122-018-0096-7. Epub 2018 Apr 6.</mixed-citation><mixed-citation xml:lang="en">Shipton EA, Shipton EE, Shipton AJ. A Review of the Opioid Epidemic: What Do We Do About It? Pain Ther. 2018 Jun;7(1):23-36. doi: 10.1007/s40122-018-0096-7. Epub 2018 Apr 6.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Trouvin AP, Berenbaum F, Perrot S. The opioid epidemic: helping rheumatologists prevent a crisis. RMD Open. 2019 Aug 6;5(2):e001029. doi: 10.1136/rmdopen-2019-001029. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Trouvin AP, Berenbaum F, Perrot S. The opioid epidemic: helping rheumatologists prevent a crisis. RMD Open. 2019 Aug 6;5(2):e001029. doi: 10.1136/rmdopen-2019-001029. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1.</mixed-citation><mixed-citation xml:lang="en">Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rasu RS, Vouthy K, Crowl AN, et al. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States. J Manag Care Spec Pharm. 2014 Sep; 20(9):921-8.</mixed-citation><mixed-citation xml:lang="en">Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Vijay A, Rhee TG, Ross JS. U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015. Prev Med. 2019 Jun; 123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.</mixed-citation><mixed-citation xml:lang="en">Rasu RS, Vouthy K, Crowl AN, et al. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States. J Manag Care Spec Pharm. 2014 Sep; 20(9):921-8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gore M, Tai KS, Sadosky A, et al. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012 Sep;12(7):550-60. doi: 10.1111/j.1533-2500.2012.00532.x. Epub 2012 Feb 5.</mixed-citation><mixed-citation xml:lang="en">Rasu RS, Vouthy K, Crowl AN, et al. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States. J Manag Care Spec Pharm. 2014 Sep; 20(9):921-8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12): 1127-46. doi: 10.2165/11633470000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Vijay A, Rhee TG, Ross JS. U.S. prescribing trends of fentanyl, opioids, and other  pain medications in outpatient and emergency department visits from 2006 to 2015. Prev Med. 2019 Jun; 123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28; 354:i4857. doi: 10.1136/bmj.i4857.</mixed-citation><mixed-citation xml:lang="en">Vijay A, Rhee TG, Ross JS. U.S. prescribing trends of fentanyl, opioids, and other  pain medications in outpatient and emergency department visits from 2006 to 2015. Prev Med. 2019 Jun; 123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362. eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Gore M, Tai KS, Sadosky A, et al. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012 Sep;12(7):550-60. doi: 10.1111/j.1533-2500.2012.00532.x. Epub 2012 Feb 5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Gore M, Tai KS, Sadosky A, et al. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012 Sep;12(7):550-60. doi: 10.1111/j.1533-2500.2012.00532.x. Epub 2012 Feb 5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">List of nationally authorised medicinal products. Active substance(s): aceclofenac. 30 November 2017 EMA/787572/2017 Human Medicines Evaluation Division. https://www.ema.europa.eu</mixed-citation><mixed-citation xml:lang="en">Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12): 1127-46. doi: 10.2165/11633470000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.drugs.com/international/aceclofenac.html</mixed-citation><mixed-citation xml:lang="en">Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12): 1127-46. doi: 10.2165/11633470000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.</mixed-citation><mixed-citation xml:lang="en">Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28; 354:i4857. doi: 10.1136/bmj.i4857.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.</mixed-citation><mixed-citation xml:lang="en">Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28; 354:i4857. doi: 10.1136/bmj.i4857.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Иголкина ЕВ, Чичасова НВ, Имаметдинова ГР. Ацеклофенак в лечении патологии опорно-двигательного аппарата. Современная ревматология. 2017;11(3):99-105. doi: 10.14412/1996-7012-2017-3-99-105</mixed-citation><mixed-citation xml:lang="en">Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362. eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Цурган АВ. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017;11(4):89-94. doi: 10.14412/1996-7012-2017-4-89-94</mixed-citation><mixed-citation xml:lang="en">Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362. eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">List of nationally authorised medicinal products. Active substance(s): aceclofenac. 30 November 2017 EMA/787572/2017 Human Medicines Evaluation Division. https://www.ema.europa.eu</mixed-citation><mixed-citation xml:lang="en">List of nationally authorised medicinal products. Active substance(s): aceclofenac. 30 November 2017 EMA/787572/2017 Human Medicines Evaluation Division. https://www.ema.europa.eu</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">List of nationally authorised medicinal products. Active substance(s): aceclofenac. 30 November 2017 EMA/787572/2017 Human Medicines Evaluation Division. https://www.ema.europa.eu</mixed-citation><mixed-citation xml:lang="en">List of nationally authorised medicinal products. Active substance(s): aceclofenac. 30 November 2017 EMA/787572/2017 Human Medicines Evaluation Division. https://www.ema.europa.eu</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.drugs.com/international/aceclofenac.html</mixed-citation><mixed-citation xml:lang="en">https://www.drugs.com/international/aceclofenac.html</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.drugs.com/international/aceclofenac.html</mixed-citation><mixed-citation xml:lang="en">https://www.drugs.com/international/aceclofenac.html</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the  management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.</mixed-citation><mixed-citation xml:lang="en">Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the  management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the  management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.</mixed-citation><mixed-citation xml:lang="en">Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the  management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.</mixed-citation><mixed-citation xml:lang="en">Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.</mixed-citation><mixed-citation xml:lang="en">Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Igolkina EV, Chichasova NV, Imametdinova GR. Aceclofenac in the treatment of diseases of the locomotor apparatus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(3):99-105. (In Russ.). doi: 10.14412/1996-7012-2017-3-99-105</mixed-citation><mixed-citation xml:lang="en">Igolkina EV, Chichasova NV, Imametdinova GR. Aceclofenac in the treatment of diseases of the locomotor apparatus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(3):99-105. (In Russ.). doi: 10.14412/1996-7012-2017-3-99-105</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Igolkina EV, Chichasova NV, Imametdinova GR. Aceclofenac in the treatment of diseases of the locomotor apparatus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(3):99-105. (In Russ.). doi: 10.14412/1996-7012-2017-3-99-105</mixed-citation><mixed-citation xml:lang="en">Igolkina EV, Chichasova NV, Imametdinova GR. Aceclofenac in the treatment of diseases of the locomotor apparatus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(3):99-105. (In Russ.). doi: 10.14412/1996-7012-2017-3-99-105</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya revmatologiya =  Modern Rheumatology Journal. 2017;11(4):89-94. (In Russ.). doi: 10.14412/1996-7012-2017-4-89-94</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya revmatologiya =  Modern Rheumatology Journal. 2017;11(4):89-94. (In Russ.). doi: 10.14412/1996-7012-2017-4-89-94</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya revmatologiya =  Modern Rheumatology Journal. 2017;11(4):89-94. (In Russ.). doi: 10.14412/1996-7012-2017-4-89-94</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya revmatologiya =  Modern Rheumatology Journal. 2017;11(4):89-94. (In Russ.). doi: 10.14412/1996-7012-2017-4-89-94</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
